Current and historical daily PE Ratio for Novonesis AS (
) from 2009 to Apr 27 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Novonesis AS stock (NVZMY) PE ratio as of Apr 27 2024 is 35.47.
More Details
Novonesis AS (NVZMY) PE Ratio (TTM) Chart
Novonesis AS (NVZMY) PE Ratio (TTM) Historical Data
View and export this data going back to 2009. Start your Free Trial
Total 1217
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Novonesis AS PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-27 | 35.5 | 2024-02-23 | 35.8 |
| 2024-04-26 | 35.5 | 2024-02-22 | 35.6 |
| 2024-04-25 | 35.2 | 2024-02-21 | 35.7 |
| 2024-04-24 | 35.4 | 2024-02-20 | 35.5 |
| 2024-04-23 | 35.5 | 2024-02-16 | 34.3 |
| 2024-04-22 | 35.0 | 2024-02-15 | 34.0 |
| 2024-04-19 | 35.0 | 2024-02-14 | 33.5 |
| 2024-04-18 | 34.6 | 2024-02-13 | 32.4 |
| 2024-04-17 | 34.9 | 2024-02-12 | 32.2 |
| 2024-04-16 | 34.7 | 2024-02-09 | 32.4 |
| 2024-04-15 | 34.6 | 2024-02-08 | 32.5 |
| 2024-04-12 | 34.8 | 2024-02-07 | 32.8 |
| 2024-04-11 | 35.5 | 2024-02-06 | 32.4 |
| 2024-04-10 | 34.5 | 2024-02-05 | 33.0 |
| 2024-04-09 | 35.0 | 2024-02-02 | 33.6 |
| 2024-04-08 | 35.9 | 2024-02-01 | 34.5 |
| 2024-04-05 | 35.9 | 2024-01-31 | 32.4 |
| 2024-04-04 | 35.8 | 2024-01-30 | 33.1 |
| 2024-04-03 | 36.4 | 2024-01-29 | 33.5 |
| 2024-04-02 | 36.4 | 2024-01-26 | 33.9 |
| 2024-04-01 | 37.1 | 2024-01-25 | 33.9 |
| 2024-03-28 | 37.4 | 2024-01-24 | 33.0 |
| 2024-03-27 | 37.4 | 2024-01-23 | 33.0 |
| 2024-03-26 | 37.8 | 2024-01-22 | 32.6 |
| 2024-03-25 | 37.5 | 2024-01-19 | 32.7 |
| 2024-03-22 | 37.7 | 2024-01-18 | 32.1 |
| 2024-03-21 | 37.3 | 2024-01-17 | 32.4 |
| 2024-03-20 | 39.3 | 2024-01-16 | 34.0 |
| 2024-03-19 | 38.1 | 2024-01-12 | 34.3 |
| 2024-03-18 | 37.8 | 2024-01-11 | 34.1 |
| 2024-03-15 | 38.0 | 2024-01-10 | 33.9 |
| 2024-03-14 | 38.8 | 2024-01-09 | 34.2 |
| 2024-03-13 | 38.8 | 2024-01-08 | 34.3 |
| 2024-03-12 | 38.8 | 2024-01-05 | 34.0 |
| 2024-03-11 | 38.6 | 2024-01-04 | 33.8 |
| 2024-03-08 | 38.8 | 2024-01-03 | 33.7 |
| 2024-03-07 | 37.7 | 2024-01-02 | 34.2 |
| 2024-03-06 | 37.0 | 2023-12-29 | 34.9 |
| 2024-03-05 | 36.7 | 2023-12-28 | 35.0 |
| 2024-03-04 | 37.0 | 2023-12-27 | 33.5 |
| 2024-03-01 | 36.3 | 2023-12-26 | 33.2 |
| 2024-02-29 | 35.9 | 2023-12-22 | 33.0 |
| 2024-02-28 | 35.5 | 2023-12-21 | 32.8 |
| 2024-02-27 | 36.0 | 2023-12-20 | 32.1 |
| 2024-02-26 | 35.9 | 2023-12-19 | 32.3 |
Novonesis AS (NVZMY) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Novonesis AS
NAICS : 325411
ISIN : US6701081092
Share Class Description:
NVZMY: ADRCompare
Compare
Traded in other countries / regions
NSIS B.Denmark0Q4U.UKNVZMY.USANZM2.GermanyNZYM.AustriaNZYM.Mexico IPO Date
2009-09-09Description
Novonesis AS formerly Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company is the world leader in industrial enzymes and microbial solutions, with a near-50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, working across more than 30 research and development and application centers and 23 manufacturing sites.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers